scholarly journals Genetic variability of DNA repair mechanisms in chemotherapy treatment outcome of gastric cancer patients

2015 ◽  
Vol 14 (4) ◽  
pp. 17228-17234 ◽  
Author(s):  
G. Zhong ◽  
H.K. Li ◽  
T. Shan ◽  
N. Zhang
Keyword(s):  
Gastric Cancer ◽  
Dna Repair ◽  
Treatment Outcome ◽  
Genetic Variability ◽  
Cancer Patients ◽  
Chemotherapy Treatment ◽  
Dna Repair Mechanisms ◽  
Repair Mechanisms ◽  
Gastric Cancer Patients

scholarly journals Genetic variability of DNA repair mechanisms influences treatment outcome of gastric cancer

2015 ◽  
Vol 10 (4) ◽  
pp. 1997-2002 ◽  
Author(s):  
CHANGMAO DING ◽  
HUIYU ZHANG ◽  
KUISHENG CHEN ◽  
CHUNLIN ZHAO ◽  
JIANBO GAO
Keyword(s):  
Gastric Cancer ◽  
Dna Repair ◽  
Treatment Outcome ◽  
Genetic Variability ◽  
Dna Repair Mechanisms ◽  
Repair Mechanisms

Genetic variability of DNA repair mechanisms and glutathione-S-transferase genes influences treatment outcome in osteosarcoma

2015 ◽  
Vol 39 (2) ◽  
pp. 182-188 ◽  
Author(s):  
Katja Goričar ◽  
Viljem Kovač ◽  
Janez Jazbec ◽  
Branko Zakotnik ◽  
Janez Lamovec ◽  
...  
Keyword(s):  
Dna Repair ◽  
Treatment Outcome ◽  
Genetic Variability ◽  
Glutathione S Transferase ◽  
Dna Repair Mechanisms ◽  
Repair Mechanisms

scholarly journals The Clinicopathological Features and Genetic Mutations in Gastric Cancer Patients According to EMAST and MSI Status

Cancers ◽  
2020 ◽  
Vol 12 (3) ◽  
pp. 551
Author(s):  
Wen-Liang Fang ◽  
Ming-Huang Chen ◽  
Kuo-Hung Huang ◽  
Shih-Ching Chang ◽  
Chien-Hsing Lin ◽  
...  
Keyword(s):  
Gastric Cancer ◽  
Dna Repair ◽  
Survival Rate ◽  
Cancer Patients ◽  
Clinicopathological Features ◽  
Akt Pathway ◽  
Genetic Mutations ◽  
Tetranucleotide Repeats ◽  
Gastric Cancer Patients ◽  
T Category

Background: There has been no report regarding the clinicopathological features and genetic mutations regarding elevated microsatellite alterations at selected tetranucleotide repeats (EMAST) in gastric cancer (GC). Methods: The correlation among EMAST status, microsatellite instability (MSI) status, mutations of common GC-related genes and 16 DNA repair-associated genes, and the clinicopathological features were analyzed. Results: Among the 360 GC patients enrolled, there were 76 (21.1%) with EMAST+ tumors and 284 with EMAST− tumors, and 59 (16.4%) were MSI-high (MSI-H) tumors, and 301 were microsatellite stable (MSS) tumors. Patients with EMAST+ tumors exhibited an earlier pathological T category and had more genetic mutations in the PI3K/AKT pathway, ARID1A and DNA repair-associated genes than those with EMAST− tumors. Patients with MSI-H tumors have more genetic mutations in the PI3K/AKT pathway and DNA repair-associated genes than those with MSS tumors. In the subgroup analysis for MSI-H GC, EMAST+ tumors were associated with earlier pathological T and N categories, earlier TNM stages, higher frequency of DNA-repair-associated genetic mutations, and a better survival rate than EMAST− tumors. Conclusions: PI3K/AKT pathway mutations may play an important role in EMAST+ and/or MSI-H GC. EMAST+/MSI-H tumors seem to represent a different subtype of gastric cancer from EMAST−/MSI-H tumors.

ERCC1 mRNA expression and XRCC1 polymorphism as predictive factors for overall survival in gastric cancer patients receiving platinum based chemotherapy

2007 ◽  
Vol 25 (18_suppl) ◽  
pp. 2512-2512 ◽  
Author(s):  
J. Wei ◽  
B. Liu ◽  
Z. Zou ◽  
X. Qian ◽  
W. Zhang ◽  
...  
Keyword(s):  
Gastric Cancer ◽  
Overall Survival ◽  
Dna Repair ◽  
Survival Time ◽  
Cancer Patients ◽  
Predictive Factors ◽  
Median Survival Time ◽  
Platinum Based Chemotherapy ◽  
Ercc1 Expression ◽  
Gastric Cancer Patients

2512 Background: DNA repair was considered to play the key role in the platinum chemotherapy. ERCC1, XPD and XRCC1, three major components of the DNA repair pathway, are critical to outcome for patients treated with platinum based chemotherapy. Methods: Overall survival times in 48 stage III (47.9%) and IV (52.1%) gastric cancer patients were investigated. mRNA was isolated from formalin- fixed paraffin-embeded pretreatment primary tumor specimens and the relative expression of ERCC1 to the internal reference geneβ-actin was measured using real-time quantitative reverse transcriptase polymerase chain reaction. Two single nucleotide polymorphisms (SNPs) (XPD Lys751Gln and XRCC1 Arg399Gln) were also investigated using 5’ nuclease allelic discrimination assay (TaqMan). Results: Median age was 55 years (range: 23 to 75 years); 35 males and 13 females; median survival time was 397 days. The median ERCC1 gene expression level from all 48 gastric tumors was 1.16, and the cutoff values for chemotherapy was 0.30. The median survival time for patients with lower ERCC1 expression (31 of 48 patients) was 496 days, compared with 218 days for patients with higher ERCC1 expression (P < 0.0001). SNP of XRCC1 Arg399Gln was measured in 47 gastric cancer patients (97.92%). Median overall survival time was longer in patients with favorite allele G in codon 399 of XRCC1 (40 of 47 patients) than in others (respectively 420 days vs 218 days, P = 0.017). No significant relationship was found between SNP of XPD Lys751Gln and outcome of gastric cancer patients. Conclusions: These findings suggested that intratumoral ERCC1 mRNA expression and polymorphism of XRCC1 might be prominent predictive factors for overall survival of gastric cancer patients treated with platinum based chemotherapy. Multi-center clinical trial has been suggested. No significant financial relationships to disclose.

scholarly journals Association of DNA Repair and Drug Transporter in Relation to Chemosensitivity in Primary Culture of Thai Gastric Cancer Patients

2018 ◽  
Vol 41 (3) ◽  
pp. 360-367 ◽  
Author(s):  
Pattama Wongsirisin ◽  
Sirikan Limpakan Yamada ◽  
Supachai Yodkeeree ◽  
Wanisa Punfa ◽  
Pornngarm Limtrakul
Keyword(s):  
Gastric Cancer ◽  
Dna Repair ◽  
Primary Culture ◽  
Cancer Patients ◽  
Drug Transporter ◽  
Gastric Cancer Patients

scholarly journals The influence of genetic variability of DNA repair mechanisms on the risk of malignant mesothelioma

2019 ◽  
Vol 53 (2) ◽  
pp. 206-212 ◽  
Author(s):  
Kristina Levpuscek ◽  
Katja Goricar ◽  
Viljem Kovac ◽  
Vita Dolzan ◽  
Alenka Franko
Keyword(s):  
Dna Repair ◽  
Genetic Variability ◽  
Malignant Mesothelioma ◽  
Odds Ratio ◽  
Asbestos Exposure ◽  
Dna Repair Mechanisms ◽  
Functional Polymorphisms ◽  
Related Disease ◽  
Repair Mechanisms ◽  
Asbestos Related Disease

Abstract Background Malignant mesothelioma (MM) is a rare aggressive tumour of mesothelium caused by asbestos exposure. It has been suggested that the genetic variability of proteins involved in DNA repair mechanisms affects the risk of MM. This study investigated the influence of functional polymorphisms in ERCC1 and XRCC1 genes, the interactions between these polymorphisms as well as the interactions between these polymorphisms and asbestos exposure on MM risk. Patients and methods In total, 237 cases with MM and 193 controls with no asbestos-related disease were genotyped for ERCC1 and XRCC1 polymorphisms. Results ERCC1 rs3212986 polymorphism was significantly associated with a decreased risk of MM (odds ratio [OR] = 0.61; 95% confidence interval [CI] = 0.41–0.91; p = 0.014). No associations were observed between other genetic polymorphisms and MM risk. Interactions between polymorphisms did not significantly influence MM risk. Interaction between ERCC1 rs11615 and asbestos exposure significantly influenced MM risk (OR = 3.61; 95% CI = 1.12–11.66; p = 0.032). Carriers of polymorphic ERCC1 rs11615 allele who were exposed to low level of asbestos had a decreased risk of MM (OR = 0.40; 95% CI = 0.19–0.84; p = 0.016). Interactions between other polymorphisms and asbestos exposure did not significantly influence MM risk. Conclusions Our findings suggest that the genetic variability of DNA repair mechanisms could contribute to the risk of developing MM.

scholarly journals Examination of RAD51 gene G135C polymorphism in gastric cancer patients in northeastern Anatolia

2019 ◽  
Vol 71 (2) ◽  
pp. 209-213
Author(s):  
Ilhami Gok ◽  
Ozkan Ozden
Keyword(s):  
Gastric Cancer ◽  
Dna Repair ◽  
Cancer Patients ◽  
Repair Gene ◽  
Repair Capacity ◽  
Dna Repair Capacity ◽  
Rad51 Gene ◽  
Genotype Frequencies ◽  
Increased Risk ◽  
Gastric Cancer Patients

Polymorphisms of DNA repair and genome integrity genes are associated with DNA repair capacity and elevated cancer risk. To establish an association between the pattern of polymorphism and the incidence of any type of cancer, studies across different populations are required. Polymorphic regions have been identified in the RAD51 repair gene in various cancer types; however, the influence of specific genetic variants on gastric cancer prevalence has not been empirically demonstrated. We conducted a case-control study with 76 gastric cancer patients and 78 healthy individuals from northeastern Anatolia to examine the association between polymorphism and gastric cancer. We genotyped the previously identified G135C polymorphism of RAD51 in all individuals and estimated the allele and genotype frequencies in the two groups. Our results indicated that the two groups differed both in allele and genotype frequencies. Additionally, a significant and elevated odd ratio (3.53) of gastric cancer for the C allele of RAD51 was observed. The genotypes GC and CC had also significant and high odd ratios (>3.75). Our results indicate that G135C polymorphism of the RAD51 gene was associated with an increased risk of gastric cancer in the examined population.

scholarly journals A 13-gene signature of DNA repair predicts prognosis in gastric cancer patients

2019 ◽  
Vol 30 ◽  
pp. ix50-ix51
Author(s):  
J. Chang ◽  
M. Xu ◽  
W. Li ◽  
H. Sun ◽  
X. Zhu
Keyword(s):  
Gastric Cancer ◽  
Dna Repair ◽  
Cancer Patients ◽  
Gene Signature ◽  
Gastric Cancer Patients
Sign in / Sign up

Export Citation Format

Share Document